Reza Nikandish - Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences
Farid Zand - Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences
Golnar Sabetian - Trauma Research Center, Shiraz University of Medical Sciences
Hajar Faghihi - Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences
Mansour Masjedi - Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences
Behzad Maghsoudi - Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences

Aim: Prophylaxis against stress ulcer in mechanically ventilated patients is one of the causes for ventilator‑associated pneumonia (VAP).Our aim was evaluating the effect of intravenous pantoprazole and ranitidine in the incidence of VAP in critically ill patients.Materials and Methods: Patients with at least 48 h of expected mechanical ventilation were allocated randomly to receive either 50 mgranitidine (R) every 8 h or 40 mg pantoprazole (P) every 12 h intravenously from admission. VAP diagnosis was according to the ClinicalPneumonia Infection Score and positive culture. Results: Eighty‑six patients during a 15‑month period were analyzed; the study showed a lowdifference between VAP incidence in the ranitidine and pantoprazole groups. No significant difference was observed in terms of gastrointestinalbleeding, intensive care unit, hospital length of stay, and mortality between the groups. Conclusion: VAP incidence is hardly related to thetype of stress ulcer prophylaxis agent with a high rate of VAP and low utilization of VAP prophylaxis bundle.

Anti‑ulcer agents, intensive care units, pneumonia